Karen Ferrante, M.D.
Dr. Ferrante, a hematologist-oncologist, was appointed to MacroGenics’ Board of Directors in January 2017. She most recently served as Chief Medical Officer and Head of Research and Development at Tokai Pharmaceuticals and brings over 20 years of oncology drug development experience to the Board. Prior to Tokai, Dr. Ferrante held several senior level positions at Millennium Pharmaceuticals and parent company Takeda Pharmaceuticals. Dr. Ferrante has also previously held positions of increasing responsibility at multiple pharmaceutical companies. She currently serves as a member of the boards of Progenics Pharmaceuticals and the New England Women in Science Executives Club. The Board believes that Dr. Ferrante’s medical training and 20 years of experience in oncology drug development qualify her to serve as a member of our Board.